Global Immune Globulins Market Size By Type (IVIg Liquid, IVIg Powder), By Application (Immunodeficiency, Autoimmune Disease), By Region, And Segment Forecasts, 2023 to 2032

The Global Immune Globulins Market was valued at USD 16.3 billion in 2023 and is projected to reach USD 29.5 billion by 2031, growing at a CAGR of 7.6% during the forecast period (2023–2031). The increasing prevalence of immunodeficiency disorders, growing applications of immunoglobulin therapies in autoimmune and neurological diseases, and expanding geriatric population are key factors driving market growth. Additionally, rising awareness and improved diagnosis of primary immunodeficiency diseases (PIDs) and the availability of advanced purification technologies are propelling the demand for immune globulin products globally.

Drivers:

1. Increasing Prevalence of Immunodeficiency Disorders:

The global burden of primary and secondary immunodeficiency disorders is rising, necessitating long-term immunoglobulin therapy. Patients with weakened immune systems, particularly due to genetic conditions or chemotherapy, significantly benefit from immune globulins.

2. Expanding Applications in Autoimmune and Neurological Conditions:

Beyond traditional use in immunodeficiency, immune globulins are increasingly used in the treatment of conditions like Guillain-Barré syndrome, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy (CIDP), broadening the market potential.

3. Growing Geriatric Population and Chronic Illnesses:

Aging populations are more susceptible to infections and chronic diseases, creating sustained demand for immunoglobulin therapy as a preventative and therapeutic solution.

Restraints:

1. High Cost of Therapy:

Immune globulin treatments are among the most expensive biological therapies, and their high cost remains a significant barrier, especially in low- and middle-income countries.

2. Limited Plasma Supply and Manufacturing Constraints:

As immune globulins are derived from human plasma, their supply is inherently limited. Stringent donor eligibility criteria and complex purification processes can limit production capacity.

Opportunity:

1. Innovation in Recombinant and Subcutaneous Immunoglobulin Products:

Advancements in recombinant technologies and the development of more patient-friendly subcutaneous formulations are expected to create new opportunities, enhancing patient compliance and treatment outcomes.

2. Rising Healthcare Infrastructure in Emerging Markets:

Developing regions are investing heavily in healthcare systems and diagnostics, enabling better diagnosis and treatment access, thereby creating untapped growth potential for immune globulin therapies.

Market by System Type Insights:

Based on product type, the Intravenous Immune Globulin (IVIG) segment held the largest market share in 2023. IVIG is widely used due to its established efficacy in treating immunodeficiencies and autoimmune diseases. However, the Subcutaneous Immune Globulin (SCIG) segment is expected to register the fastest growth, owing to its convenience for home-based administration and fewer systemic side effects.

Market by End-use Insights:

By end-use, Hospitals dominated the market in 2023, accounting for the highest revenue share, driven by the availability of sophisticated infrastructure and trained professionals for IVIG administration. Homecare settings are expected to grow rapidly due to increasing preference for self-administered SCIG treatments and efforts to reduce hospital stays and associated costs.

Market by Regional Insights:

North America led the global immune globulins market in 2023, attributed to high healthcare spending, advanced medical infrastructure, and strong plasma collection systems. Asia-Pacific is poised to grow at the fastest pace, supported by increasing healthcare investments, growing awareness of immunodeficiencies, and improving access to immunoglobulin therapies in countries such as China and India.

Competitive Scenario:

Leading companies in the immune globulins market include Grifols S.A., CSL Behring, Takeda Pharmaceutical Company Limited, Kedrion Biopharma, Octapharma AG, Bio Products Laboratory Ltd., Biotest AG, and ADMA Biologics. These players are focusing on expanding plasma collection centers, innovating in recombinant product pipelines, and engaging in strategic mergers and collaborations to gain market share.

Scope of Work – Global Immune Globulins Market

Key Market Developments:

2023: Takeda announced expansion of its SCIG product portfolio for CIDP patients, receiving positive reimbursement decisions in the EU.

2024: Grifols launched a next-gen plasma fractionation facility in the U.S., boosting global immune globulin production capacity.

2025: CSL Behring partnered with emerging biotech firms to develop recombinant immunoglobulin therapies targeting rare autoimmune diseases.

FAQs:

1) What is the current market size of the Global Immune Globulins Market?

The Global Immune Globulins Market was valued at USD 16.3 billion in 2023.

2) What is the major growth driver of the Global Immune Globulins Market?

Rising prevalence of immunodeficiency and autoimmune diseases is a key growth driver.

3) Which is the largest region during the forecast period in the Global Immune Globulins Market?

North America holds the largest market share due to advanced healthcare infrastructure and plasma collection capabilities.

4) Which segment accounted for the largest market share in Global Immune Globulins Market?

The Intravenous Immune Globulin (IVIG) segment led the market in 2023.

5) Who are the key market players in the Global Immune Globulins Market?

Key players include Grifols S.A., CSL Behring, Takeda, Kedrion Biopharma, and Octapharma AG.